Number of participants experiencing any serious adverse events · MCI
1 finding from 1 review
Adverse events and complications · people with liver metastases
1 finding from 1 review
Adverse events and complications · people with liver metastases
1 finding from 1 review
Adverse events and complications · people with liver metastases
1 finding from 1 review
Adverse events or toxicity: differences in rates of specific adverse events · people with sickle cell disease
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Clobazam (low, medium and high doses) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Felbamate plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Lamotrigine plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Rufinamide plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Cannabidiol (10 mg/kg and 20 mg/kg) plus ASMs leads to higher number of participants with adverse events leading to study… compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with adverse events ‐ muscle weakness (up to longest · children and adults with sepsis
Corticosteroids leads to higher number of participants with adverse events ‐ muscle weakness (up to… compared with placebo or usual care (high certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as adverse events requiring withdrawal of… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Number of participants with any adverse events№ of participants: 102(2 RCTs) · idiopathic hypersomnia
Modafinil showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).
1 finding from 1 review
OR 1.68 [0.28, 9.94]
Studies not reported
Low
Adverse events ‐ nervous system disorders ‐ total nervous system disorders ( · diagnosis of dementia (dementia in Alzheimer’s disease, vascular dementia, or mixed dementia; any severity
Comparison: cannabinoids showed no clear difference in adverse events ‐ nervous system disorders ‐ total nervous system… compared with placebo (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · women with subfertility
Antioxidant(s) showed no clear difference in adverse events ‐ Gastrointestinal disturbances№ of participants:… compared with placebo or no treatment/standard treatment (low certainty).
1 finding from 1 review
Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review